Stockscreener 앱 받기
32.78
1.50%
-0.50
시간 외 거래:
32.78
전일 마감가:
$33.28
열려 있는:
$32.96
하루 거래량:
835.32K
Relative Volume:
1.02
시가총액:
$2.60B
수익:
$517.15M
순이익/손실:
$66.35M
주가수익비율:
39.92
EPS:
0.8212
순현금흐름:
$126.63M
1주 성능:
+5.98%
1개월 성능:
-9.65%
6개월 성능:
-3.90%
1년 성능:
+3.15%
1일 변동 폭
$32.40
$33.43
1주일 범위
$31.06
$33.70
52주 변동 폭
$22.61
$50.71
Veracyte Inc Stock (VCYT) Company Profile
명칭
Veracyte Inc
전화
(650) 243-6300
주소
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
32.78 | 2.64B | 517.15M | 66.35M | 126.63M | 0.8212 |
|
TMO
Thermo Fisher Scientific Inc
|
470.21 | 172.63B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
190.11 | 135.42B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
579.85 | 45.95B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
111.75 | 31.51B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
299.57 | 28.94B | 3.17B | 642.63M | 516.49M | 10.77 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-02 | 재개 | Morgan Stanley | Underweight |
| 2025-10-20 | 개시 | Canaccord Genuity | Hold |
| 2025-03-20 | 개시 | Craig Hallum | Buy |
| 2024-12-05 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-16 | 개시 | UBS | Buy |
| 2024-10-10 | 개시 | Guggenheim | Buy |
| 2024-02-23 | 재확인 | Needham | Buy |
| 2023-01-18 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-01-07 | 개시 | Stephens | Overweight |
| 2021-11-18 | 재개 | Goldman | Buy |
| 2021-06-15 | 개시 | Raymond James | Outperform |
| 2021-02-18 | 재개 | Needham | Buy |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2020-09-09 | 개시 | Morgan Stanley | Underweight |
| 2019-07-31 | 개시 | Lake Street | Buy |
| 2019-07-02 | 개시 | Needham | Buy |
| 2018-11-29 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-10-31 | 업그레이드 | Janney | Neutral → Buy |
| 2017-11-07 | 다운그레이드 | Janney | Buy → Neutral |
| 2017-11-07 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-08-31 | 재개 | BTIG Research | Buy |
| 2016-11-14 | 재개 | Leerink Partners | Outperform |
| 2015-12-18 | 개시 | Cantor Fitzgerald | Buy |
| 2015-06-11 | 재확인 | Leerink Partners | Outperform |
| 2013-11-26 | 개시 | William Blair | Outperform |
모두보기
Veracyte Inc 주식(VCYT)의 최신 뉴스
Does Veracyte (VCYT) offer both strength and opportunity? - MSN
Breakouts Watch: Can Veracyte Inc expand into new marketsQuarterly Growth Report & Real-Time Volume Spike Alerts - baoquankhu1.vn
How Veracyte’s New AI-Focused CTO Role At Veracyte (VCYT) Has Changed Its Investment Story - simplywall.st
Veracyte appoints Kevin Haas as chief development officer - Investing.com India
Veracyte appoints Kevin Haas as chief development officer By Investing.com - Investing.com South Africa
Veracyte CFO Chambers sells $662k in VCYT stock - Investing.com Nigeria
Veracyte (VCYT) Appoints New Chief Development and Technology Of - GuruFocus
Veracyte names Kevin Haas as Chief Development and Technology Officer - TipRanks
Veracyte names Kevin Haas as chief development and technology officer - marketscreener.com
Veracyte Names Kevin Haas As Chief Development And Technology Officer - TradingView
Veracyte Appoints Kevin Haas as Chief Technology Leader - TipRanks
Veracyte Appoints Kevin Haas as Chief Development and Technology Officer - marketscreener.com
Veracyte (NASDAQ: VCYT) hires Kevin Haas as Chief Development and Technology Officer - Stock Titan
Veracyte Names Kevin Haas as Chief Development and Technology Officer - The Joplin Globe
Veracyte, Inc. Appoints Kevin Haas as Chief Development and Technology Officer, Effective March 24, 2026 - marketscreener.com
Iron Triangle Partners LP Purchases New Position in Veracyte, Inc. $VCYT - MarketBeat
Fred Alger Management LLC Takes $26.35 Million Position in Veracyte, Inc. $VCYT - MarketBeat
Bamco Inc. NY Decreases Stake in Veracyte, Inc. $VCYT - MarketBeat
Veracyte, Inc. $VCYT is ArrowMark Colorado Holdings LLC's 7th Largest Position - MarketBeat
Veracyte Inc Stock (ISIN: US92347M1009) Holds Steady Amid Analyst Downgrade and Mixed Signals - AD HOC NEWS
Veracyte (NASDAQ:VCYT) Downgraded by Zacks Research to "Hold" - MarketBeat
Veracyte, Inc. $VCYT Stock Holdings Lifted by First Trust Advisors LP - MarketBeat
Veracyte (VCYT) CAO awarded 10,525 RSUs in new equity grant - Stock Titan
Veracyte (NASDAQ: VCYT) SVP Annie McGuire receives new stock awards - Stock Titan
Veracyte (NASDAQ: VCYT) CCO granted new restricted stock units - Stock Titan
Veracyte (VCYT) grants CEO Marc Stapley 92,099 RSUs vesting from 2027 - Stock Titan
Veracyte (VCYT) CFO receives restricted stock unit grants boosting holdings - Stock Titan
Veracyte, Inc. (NASDAQ:VCYT) Q2 2025 Earnings Call Transcript - MSN
Panic Selling: Can Veracyte Inc. ride the EV waveWeekly Trade Analysis & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Veracyte at Leerink Global Healthcare: Strategic Growth Focus By Investing.com - Investing.com Canada
Are Veracyte's (VCYT) Strong 2025 Profits and Reaffirmed 2026 Outlook Redefining Its Growth Story? - simplywall.st
Veracyte CFO Chambers sells $662k in VCYT stock By Investing.com - Investing.com Canada
Insider Sell: Rebecca Chambers Sells Shares of Veracyte Inc (VCY - GuruFocus
UBS reaffirmed buy rating on Veracyte (VCYT) after strong Q4 testing revenue - MSN
Veracyte (NASDAQ:VCYT) CFO Rebecca Chambers Sells 18,341 Shares - MarketBeat
Veracyte (VCYT) CFO executes Rule 10b5-1 stock sale - Stock Titan
Veracyte (VCYT) CEO sells 45,523 shares under pre-set 10b5-1 plan - Stock Titan
Veracyte (VCYT) CCO Leite sells 5,260 shares under Rule 10b5-1 plan - Stock Titan
VCYT: Morgan Stanley Lowers Price Target Amidst Underweight Rati - GuruFocus
Morgan Stanley Lowers Price Target on Veracyte to $37 From $48, Keeps Underweight Rating - marketscreener.com
Morgan Stanley cuts Veracyte stock price target on valuation methodology By Investing.com - Investing.com Canada
Morgan Stanley cuts Veracyte stock price target on valuation methodology - Investing.com
Veracyte, Inc. $VCYT Shares Sold by GW&K Investment Management LLC - MarketBeat
Veracyte, Inc. $VCYT Shares Acquired by ARK Investment Management LLC - MarketBeat
Affiliate to sell 6,658 Restricted Stock Units — VCYT (NASDAQ: VCYT) - Stock Titan
[144] VERACYTE, INC. SEC Filing - Stock Titan
Marc Stapley (NASDAQ: VCYT) reports sale of 15,000 shares for $1.92M - Stock Titan
Veracyte Insider Sold Shares Worth $485,429, According to a Recent SEC Filing - marketscreener.com
Veracyte (NASDAQ: VCYT) VP has 3,006 shares withheld for taxes - Stock Titan
Veracyte (VCYT) CFO reports 7,234-share tax withholding, not a sale - Stock Titan
[Form 4] VERACYTE, INC. Insider Trading Activity - Stock Titan
Veracyte Inc (VCYT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.55%
2.50%
자본화:
|
볼륨(24시간):